{"id":"NCT00264810","sponsor":"NeuroPace","briefTitle":"RNS® System Pivotal Study","officialTitle":"RNS® System Pivotal-A Clinical Investigation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-12","primaryCompletion":"2009-10","completion":"2011-05","firstPosted":"2005-12-13","resultsPosted":"2013-08-28","lastUpdate":"2013-08-28"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"PROCEDURE","name":"RNS® System implantation","otherNames":[]},{"type":"DEVICE","name":"RNS® System responsive stimulation","otherNames":[]}],"arms":[{"label":"Treatment Group (stimulation ON)","type":"ACTIVE_COMPARATOR"},{"label":"Sham Group (stimulation OFF)","type":"SHAM_COMPARATOR"}],"summary":"The RNS® System Pivotal study is designed to assess safety and demonstrate that the RNS® System is effective as an adjunctive (add-on) therapy in reducing the frequency of seizures in individuals 18 years of age or older with partial onset seizures from no more than two foci (two areas of the brain) that are refractory (drug-resistant or hard-to-treat) to two or more antiepileptic medications. Patients continue to receive their epilepsy medications while participating in the study.","primaryOutcome":{"measure":"Acute SAE Rate","timeFrame":"Initial implant through 1 month post-implant","effectByArm":[{"arm":"Implanted Subjects","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":32,"countries":["United States"]},"refs":{"pmids":["9218289","12378060","17691324","17709978","11781412","11948772","11948774","11391740","12015845","19199440","19129963","21917777","25819949"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":49,"n":97},"commonTop":["Implant site pain","Nasopharyngitis","Procedural headache","Headache","Therapeutic agent toxicity"]}}